Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07359443Phase 1Recruiting

Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma

Role: collaborator

NCT07294794Not ApplicableNot Yet Recruiting

Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension

Role: collaborator

NCT04156945Not ApplicableActive Not Recruiting

Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men

Role: collaborator

All 3 trials loaded